Plasma levels of S100A4 in portopulmonary hypertension

Tien Peng, Roham Zamanian, Michael Joseph Krowka, Raymond L. Benza, Kari E. Roberts, Darren B. Taichman, Debbie Rybak, James F. Trotter, Robert S. Brown, Michael B. Fallon, Steven M. Kawut

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

We previously showed that a single nucleotide polymorphism in S100A4 was associated with portopulmonary hypertension (PPHTN) in patients with advanced liver disease. We aimed to determine the association between plasma levels of S100A4 and PPHTN. We performed a casecontrol study of patients with advanced liver disease. Cases with PPHTN had mean pulmonary artery pressure >25mmHg, pulmonary vascular resistance >240 dynes scm-5 and pulmonary capillary wedge pressure ≤15mmHg. Controls with liver disease had right ventricular systolic pressure <40mmHg and normal right atrial and ventricular morphology by echocardiography. Plasma samples were assayed for S100A4. The study sample included 14 cases with PPHTN and 32 controls with liver disease. There was no difference in mean age between cases and controls (p 0.52). Seventy-nine percent of cases were female compared with 44% of controls (p0.03). There was no difference in S100A4 levels between cases and controls (p0.58). Both groups had significantly higher S100A4 levels than healthy volunteers (p<0.05). There was no significant difference in plasma levels of S100A4 between PPHTN patients and controls with liver disease, although liver disease itself was associated with increased S100A4 levels.

Original languageEnglish (US)
Pages (from-to)156-160
Number of pages5
JournalBiomarkers
Volume14
Issue number3
DOIs
StatePublished - May 2009

Fingerprint

Liver
Liver Diseases
Hypertension
Plasmas
Echocardiography
Pulmonary Wedge Pressure
Capillarity
Ventricular Pressure
Polymorphism
Vascular Resistance
Pulmonary Artery
Single Nucleotide Polymorphism
Healthy Volunteers
Nucleotides
Association reactions
Blood Pressure
Pressure

Keywords

  • Genetic susceptibility
  • Portal hypertension
  • Pulmonary arterial hypertension
  • S100A4

ASJC Scopus subject areas

  • Biochemistry
  • Clinical Biochemistry
  • Health, Toxicology and Mutagenesis
  • Medicine(all)

Cite this

Peng, T., Zamanian, R., Krowka, M. J., Benza, R. L., Roberts, K. E., Taichman, D. B., ... Kawut, S. M. (2009). Plasma levels of S100A4 in portopulmonary hypertension. Biomarkers, 14(3), 156-160. https://doi.org/10.1080/13547500902773896

Plasma levels of S100A4 in portopulmonary hypertension. / Peng, Tien; Zamanian, Roham; Krowka, Michael Joseph; Benza, Raymond L.; Roberts, Kari E.; Taichman, Darren B.; Rybak, Debbie; Trotter, James F.; Brown, Robert S.; Fallon, Michael B.; Kawut, Steven M.

In: Biomarkers, Vol. 14, No. 3, 05.2009, p. 156-160.

Research output: Contribution to journalArticle

Peng, T, Zamanian, R, Krowka, MJ, Benza, RL, Roberts, KE, Taichman, DB, Rybak, D, Trotter, JF, Brown, RS, Fallon, MB & Kawut, SM 2009, 'Plasma levels of S100A4 in portopulmonary hypertension', Biomarkers, vol. 14, no. 3, pp. 156-160. https://doi.org/10.1080/13547500902773896
Peng T, Zamanian R, Krowka MJ, Benza RL, Roberts KE, Taichman DB et al. Plasma levels of S100A4 in portopulmonary hypertension. Biomarkers. 2009 May;14(3):156-160. https://doi.org/10.1080/13547500902773896
Peng, Tien ; Zamanian, Roham ; Krowka, Michael Joseph ; Benza, Raymond L. ; Roberts, Kari E. ; Taichman, Darren B. ; Rybak, Debbie ; Trotter, James F. ; Brown, Robert S. ; Fallon, Michael B. ; Kawut, Steven M. / Plasma levels of S100A4 in portopulmonary hypertension. In: Biomarkers. 2009 ; Vol. 14, No. 3. pp. 156-160.
@article{8ea38a5360d34a368cc231090ba13cab,
title = "Plasma levels of S100A4 in portopulmonary hypertension",
abstract = "We previously showed that a single nucleotide polymorphism in S100A4 was associated with portopulmonary hypertension (PPHTN) in patients with advanced liver disease. We aimed to determine the association between plasma levels of S100A4 and PPHTN. We performed a casecontrol study of patients with advanced liver disease. Cases with PPHTN had mean pulmonary artery pressure >25mmHg, pulmonary vascular resistance >240 dynes scm-5 and pulmonary capillary wedge pressure ≤15mmHg. Controls with liver disease had right ventricular systolic pressure <40mmHg and normal right atrial and ventricular morphology by echocardiography. Plasma samples were assayed for S100A4. The study sample included 14 cases with PPHTN and 32 controls with liver disease. There was no difference in mean age between cases and controls (p 0.52). Seventy-nine percent of cases were female compared with 44{\%} of controls (p0.03). There was no difference in S100A4 levels between cases and controls (p0.58). Both groups had significantly higher S100A4 levels than healthy volunteers (p<0.05). There was no significant difference in plasma levels of S100A4 between PPHTN patients and controls with liver disease, although liver disease itself was associated with increased S100A4 levels.",
keywords = "Genetic susceptibility, Portal hypertension, Pulmonary arterial hypertension, S100A4",
author = "Tien Peng and Roham Zamanian and Krowka, {Michael Joseph} and Benza, {Raymond L.} and Roberts, {Kari E.} and Taichman, {Darren B.} and Debbie Rybak and Trotter, {James F.} and Brown, {Robert S.} and Fallon, {Michael B.} and Kawut, {Steven M.}",
year = "2009",
month = "5",
doi = "10.1080/13547500902773896",
language = "English (US)",
volume = "14",
pages = "156--160",
journal = "Biomarkers",
issn = "1354-750X",
publisher = "Informa Healthcare",
number = "3",

}

TY - JOUR

T1 - Plasma levels of S100A4 in portopulmonary hypertension

AU - Peng, Tien

AU - Zamanian, Roham

AU - Krowka, Michael Joseph

AU - Benza, Raymond L.

AU - Roberts, Kari E.

AU - Taichman, Darren B.

AU - Rybak, Debbie

AU - Trotter, James F.

AU - Brown, Robert S.

AU - Fallon, Michael B.

AU - Kawut, Steven M.

PY - 2009/5

Y1 - 2009/5

N2 - We previously showed that a single nucleotide polymorphism in S100A4 was associated with portopulmonary hypertension (PPHTN) in patients with advanced liver disease. We aimed to determine the association between plasma levels of S100A4 and PPHTN. We performed a casecontrol study of patients with advanced liver disease. Cases with PPHTN had mean pulmonary artery pressure >25mmHg, pulmonary vascular resistance >240 dynes scm-5 and pulmonary capillary wedge pressure ≤15mmHg. Controls with liver disease had right ventricular systolic pressure <40mmHg and normal right atrial and ventricular morphology by echocardiography. Plasma samples were assayed for S100A4. The study sample included 14 cases with PPHTN and 32 controls with liver disease. There was no difference in mean age between cases and controls (p 0.52). Seventy-nine percent of cases were female compared with 44% of controls (p0.03). There was no difference in S100A4 levels between cases and controls (p0.58). Both groups had significantly higher S100A4 levels than healthy volunteers (p<0.05). There was no significant difference in plasma levels of S100A4 between PPHTN patients and controls with liver disease, although liver disease itself was associated with increased S100A4 levels.

AB - We previously showed that a single nucleotide polymorphism in S100A4 was associated with portopulmonary hypertension (PPHTN) in patients with advanced liver disease. We aimed to determine the association between plasma levels of S100A4 and PPHTN. We performed a casecontrol study of patients with advanced liver disease. Cases with PPHTN had mean pulmonary artery pressure >25mmHg, pulmonary vascular resistance >240 dynes scm-5 and pulmonary capillary wedge pressure ≤15mmHg. Controls with liver disease had right ventricular systolic pressure <40mmHg and normal right atrial and ventricular morphology by echocardiography. Plasma samples were assayed for S100A4. The study sample included 14 cases with PPHTN and 32 controls with liver disease. There was no difference in mean age between cases and controls (p 0.52). Seventy-nine percent of cases were female compared with 44% of controls (p0.03). There was no difference in S100A4 levels between cases and controls (p0.58). Both groups had significantly higher S100A4 levels than healthy volunteers (p<0.05). There was no significant difference in plasma levels of S100A4 between PPHTN patients and controls with liver disease, although liver disease itself was associated with increased S100A4 levels.

KW - Genetic susceptibility

KW - Portal hypertension

KW - Pulmonary arterial hypertension

KW - S100A4

UR - http://www.scopus.com/inward/record.url?scp=66149157297&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=66149157297&partnerID=8YFLogxK

U2 - 10.1080/13547500902773896

DO - 10.1080/13547500902773896

M3 - Article

C2 - 19399660

AN - SCOPUS:66149157297

VL - 14

SP - 156

EP - 160

JO - Biomarkers

JF - Biomarkers

SN - 1354-750X

IS - 3

ER -